Question: Must the AroCell TK 210 ELISA kit be modified for each type of cancer?
Answer: The AroCell TK 210 ELISA is a biomarker of cellular proliferation, a common characteristic of cancers, therefore it should be widely applicable.
However, the types of cancer where the AroCell TK 210 ELISA biomarker is most valuable as a diagnostic aid have not yet been established. Clinical trials are ongoing.
Question: Why do you think that physicians will want to use the AroCell TK 210 ELISA kit in the near future?
Answer: We believe that the AroCell TK 210 ELISA kit provides unique new information on patient disease process using a method which is applicable to the technology and instrumentation already in routine use in health care. The AroCell TK 210 ELISA results can be combined with those of existing biomarkers of tumor mass (for example PSA and Ca 15-3) to enable more accurate prognoses and better therapy monitoring. Of course, this must be verified in the final results of currently ongoing clinical trials.
Question: How does the AroCell TK 210 ELISA serum biomarker compare with other tumor biomarkers?
Answer: Most tumor biomarkers provide an indication of tumor mass. The potential value of the AroCell TK 210 ELISA serum biomarker provides and indication of tumor growth, both may be valuable individually and complementary to each other in biomarker panels.
For example, in a study on subjects with breast cancer, the AroCell TK 210 ELISA biomarker showed better discrimination between healthy individuals and subjects with Stage 2 breast cancer than the traditional biomarker Ca 15-3. Even more importantly, the combination of Ca 15-3 and TK 210 ELISA increased the diagnostic accuracy still more, demonstrating the value of combining biomarkers that monitor different aspects of tumor growth (Kumar JK et al 2016 Tumor Biology).